Evaluation of Pharmacist’s Intervention in Improving Treatment Outcomes of Rheumatoid Arthritis: A Randomized Controlled Trial

Overview

Rheumatoid arthritis is an auto-immune disorders that mainly affects the joints. It may also affect other organs of the body such as skin, eyes, lungs and heart. The immune system of the body attacks the lining of the joint that results in erosion and joint deformity. This condition if untreated may lead to disability. RA is managed by medications known as disease modifying anti rheumatic drugs (DMARDs) as well as physical therapy. Dietary and lifestyle modification may also ease the condition.

Full Title of Study: “Evaluation of Pharmacist’s Intervention in Improving Treatment Outcomes of Rheumatoid Arthritis Patients in Karachi, Pakistan: The Pharmacist Assisted Care Trial for Rheumatoid Arthritis Patients (PACTRA)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Health Services Research
    • Masking: Double (Investigator, Outcomes Assessor)
  • Study Primary Completion Date: August 1, 2018

Detailed Description

One of the major problems in managing RA is adherence to rehabilitation and medication. Studies report low adherence to medication among patients of RA. Certain barriers to rehabilitation also exists which may include exhaustive treatment attendance, time management and direct costs. Patient intentionally make decisions of non adherence to their prescribed rehabilitation schedule and medication regimen. This may be due to suffering from adverse drug reactions (ADRs) of medications, excessive pain arising from physical therapy and/or out-of-pocket costs.

Pharmacists have the potential to improve the patient's clinical, humanistic and economic outcomes in rheumatoid arthritis by providing pharmaceutical care. This can be executed by:

1. Resolving drug related problems and managing drug therapy

2. Management of modifiable risk factors such as weight

3. Recommending dietary and lifestyle changes

4. Providing patient counseling, disease education and medication advice

5. Reducing the out-of-pocket costs

6. Improve overall well being and quality of life

Evidence from the past indicates a varying prevalence of RA in Pakistan. Figures for prevalence of RA varied geographically as literature reported a prevalence of 0.142% to 5.5% in the southern and northern region of Pakistan respectively. Recently, a study conducted in a tertiary care unit in the city of Karachi located in southern region reported a figure of 633 (12.9%) for RA patients out of total 4900 patients who visited rheumatology clinic in the hospital. It highlighted that disease burden in this region has dramatically increased.

Most Pakistani patients lack adequate disease knowledge and awareness regarding RA. Moreover, patients in Pakistan have to pay direct medical cost in most of the cases. In the past, studies have highlighted that Pakistani patients view costs per session and treatment attendance as major barriers to undergo physical therapy sessions for rheumatological disorders.

There is a dearth of literature reported on pharmacist's inclusion to improve treatment outcomes in rheumatoid arthritis.There are no reported figures for adherence to treatment and medications for RA or any musculoskeletal disease. Studies conducted in Pakistan also highlight that pharmacists have the potential to improve economic, clinical and humanistic outcomes by providing pharmaceutical care to patients. However, it is to be seen if pharmacist can actually achieve the milestone i.e. improve patient treatment outcomes of rheumatoid arthritis. A randomized trial is therefore needed employing pharmacist intervention in RA patients. This present an excellent opportunity to identify the areas where a pharmacist has the potential to play his/her role and evaluate its effectiveness.

Interventions

  • Other: Pharmacist led pharmaceutical care
    • The intervention in the study will be a pharmacist’s intervention that will be provided to rheumatoid arthritis patients in order to improve their treatment outcomes. It will be in the form of a single (1) session by pharmacist (face-to-face) followed by written material for use at home. The pharmacist will look at the patient’s baseline data and provide counseling. The venue for counseling will be the hospitals.

Arms, Groups and Cohorts

  • Experimental: Pharmacist intervention
    • Disease education (General education about rheumatoid arthritis in a verbal and written manner) Dietary and lifestyle modifications (General recommendations as well as specific ones based on patients’ baseline health status) Counseling regarding adherence (General lecture on adherence to medications and physical rehabilitation in rheumatoid arthritis as well as specific advice based on patients health status) Advice on medication use (General counseling on medication use as well as patient centered counseling).
  • No Intervention: Usual care
    • Patients will not be counseled by pharmacist and will be allowed to take usual care.

Clinical Trial Outcome Measures

Primary Measures

  • Disease knowledge
    • Time Frame: Week 12 from baseline
    • Knowledge about rheumatoid arthritis
  • Medication Adherence
    • Time Frame: Week 12 from baseline
    • Patients’ adherence to their medications
  • Health Related Quality of Life (HR-QOL)
    • Time Frame: Week 12 from baseline
    • Rheumatoid arthritis patients’ health related quality of life
  • Treatment Adherence
    • Time Frame: Week 12 from baseline
    • Patients’ adherence to their rehabilitation
  • Direct Cost
    • Time Frame: Week 12 from baseline
    • Direct cost of rheumatoid arthritis treatment on patient’s pocket

Secondary Measures

  • Patient satisfaction
    • Time Frame: At Week 12
    • Patient satisfaction from pharmacists in managing rheumatoid arthritis

Participating in This Clinical Trial

Inclusion Criteria

  • Out-patients with established diagnosis of rheumatoid arthritis over 3 months.
  • Participants who are willing to participate in the study.

Exclusion Criteria

  • Patients with no rheumatoid arthritis.
  • Patients currently undergoing surgery or had previous history of surgery.
  • Patients with more than 3 comorbidities.
  • Patients who are not willing to participate.
  • In-patients will not be included.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Science Malaysia
  • Provider of Information About this Clinical Study
    • Principal Investigator: Atta Abbas Naqvi, Atta Abbas Naqvi – University of Science Malaysia
  • Overall Official(s)
    • Azmi A Hassali, PhD, Study Director, University of Science Malaysia

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.